• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病全球诊断、管理和预防策略(GOLD)2011年修订版——为何修订及修订内容?

The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)--why and what?

作者信息

Vestbo Jørgen, Hurd Suzanne S, Rodriguez-Roisin Roberto

机构信息

Department of Respiratory Medicine J, Odense University Hospital, Odense, Denmark.

出版信息

Clin Respir J. 2012 Oct;6(4):208-14. doi: 10.1111/crj.12002.

DOI:10.1111/crj.12002
PMID:22906068
Abstract

INTRODUCTION

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published a strategy for diagnosis and for management of chronic obstructive pulmonary disease (COPD) since 2001 and this has formed the basis for numerous national and regional guidelines.

OBJECTIVES

We describe the background for the 2011 revision of the GOLD document.

METHODS

The GOLD document is updated annually and revised every 5 years based on published research as well as an evaluation by an expert panel of how to best formulate and disseminate knowledge on COPD.

RESULTS

The GOLD 2011 revision states that spirometry is required for making a clinical diagnosis of COPD. At the same time, the document has less emphasis on spirometric evaluation of disease severity and launches a combined assessment taking symptoms, spirometry and history of exacerbations into account. This is matched with initial treatment for COPD where smoking cessation, pulmonary rehabilitation and physical activity in general are given high priority followed by pharmacologic treatment guided by the novel assessment scheme. Comorbidities are often present in COPD and the GOLD 2011 revision gives some guidance in how to manage these as well as how to manage COPD in the presence of comorbidities.

CONCLUSION

A more clinically oriented GOLD document will hopefully improve assessment and management of COPD.

摘要

引言

自2001年以来,慢性阻塞性肺疾病全球倡议组织(GOLD)发布了慢性阻塞性肺疾病(COPD)的诊断和管理策略,这已成为众多国家和地区指南的基础。

目的

我们描述GOLD文件2011年修订版的背景。

方法

GOLD文件每年更新,并根据已发表的研究以及专家小组对如何最佳制定和传播COPD知识的评估,每5年修订一次。

结果

GOLD 2011修订版指出,临床诊断COPD需要进行肺功能测定。同时,该文件对疾病严重程度的肺功能评估的重视程度降低,并推出了一种综合评估方法,将症状、肺功能测定和急性加重史考虑在内。这与COPD的初始治疗相匹配,其中戒烟、肺康复和一般体育活动被高度优先考虑,随后是根据新的评估方案进行药物治疗。COPD患者常伴有合并症,GOLD 2011修订版对如何管理这些合并症以及在存在合并症的情况下如何管理COPD提供了一些指导。

结论

一份更以临床为导向的GOLD文件有望改善COPD的评估和管理。

相似文献

1
The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)--why and what?慢性阻塞性肺疾病全球诊断、管理和预防策略(GOLD)2011年修订版——为何修订及修订内容?
Clin Respir J. 2012 Oct;6(4):208-14. doi: 10.1111/crj.12002.
2
Guideline for the management of chronic obstructive pulmonary disease--2011 update.慢性阻塞性肺疾病管理指南——2011 年更新版。
S Afr Med J. 2011 Jan;101(1 Pt 2):63-73.
3
Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision.慢性阻塞性肺疾病(COPD)管理指南:2004年修订版
S Afr Med J. 2004 Jul;94(7 Pt 2):559-75.
4
The 2007 GOLD Guidelines: a comprehensive care framework.《2007年慢性阻塞性肺疾病全球倡议指南》:一个全面的护理框架。
Respir Care. 2009 Aug;54(8):1040-9.
5
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.慢性阻塞性肺疾病诊断、管理和预防全球策略:GOLD执行摘要
Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. doi: 10.1164/rccm.200703-456SO. Epub 2007 May 16.
6
The GOLD initiative 2011: a change of paradigm?GOLD 倡议 2011:范式转变?
Arch Bronconeumol. 2012 Aug;48(8):286-9. doi: 10.1016/j.arbres.2012.02.018. Epub 2012 Apr 24.
7
A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD.慢性阻塞性肺疾病患者诊断与治疗的全球慢性阻塞性肺疾病倡议(GOLD)指南综述。
Int J Clin Pract. 2008 Aug;62(8):1219-36. doi: 10.1111/j.1742-1241.2008.01807.x. Epub 2008 Jun 28.
8
Preventing chronic obstructive pulmonary disease: what is known and what needs to be done to make a difference to the patient?预防慢性阻塞性肺疾病:目前已知的情况以及为改善患者状况需要采取的措施?
Am J Med. 2007 Aug;120(8 Suppl 1):S14-22. doi: 10.1016/j.amjmed.2007.04.008.
9
[Diagnostic and treatment of chronic obstructive pulmonary disease based on GOLD statement 2011].基于2011年慢性阻塞性肺疾病全球倡议声明的慢性阻塞性肺疾病诊断与治疗
Pol Merkur Lekarski. 2012 Oct;33(196):187-92.
10
COPD management. Part I. Strategies for managing the burden of established COPD.慢性阻塞性肺疾病的管理。第一部分。应对已确诊慢性阻塞性肺疾病负担的策略。
Int J Tuberc Lung Dis. 2008 Jun;12(6):586-94.

引用本文的文献

1
Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS).新冠后综合征治疗的随机适应性评估(RAPID):一项针对新冠后综合征(PCS)患者身体功能治疗方案的多中心、随机、对照适应性平台试验的研究方案,包括首个特定干预附录RAPID_REVIVE(降低PCS患者的炎症活动)。
Trials. 2025 Aug 19;26(1):297. doi: 10.1186/s13063-025-09008-0.
2
Relationship between Severity of Chronic Obstructive Pulmonary Disease and Left Ventricular Diastolic Dysfunction.慢性阻塞性肺疾病严重程度与左心室舒张功能障碍的关系
Tanaffos. 2024 Mar;23(3):294-299.
3
CAT score as a prognostic tool in low resource setting: Exploring the correlation between CAT score, exacerbation history with BODE Index in stable COPD.在资源匮乏环境中,CAT评分作为一种预后工具:探究稳定期慢性阻塞性肺疾病患者CAT评分、急性加重病史与BODE指数之间的相关性
Lung India. 2025 Jul 1;42(4):343-346. doi: 10.4103/lungindia.lungindia_633_24. Epub 2025 Jun 27.
4
Adherence to Pharmacological Management Guidelines for Stable Chronic Obstructive Lung Disease.遵循稳定期慢性阻塞性肺疾病的药物治疗指南
Tuberc Respir Dis (Seoul). 2025 Apr;88(2):310-321. doi: 10.4046/trd.2024.0130. Epub 2025 Feb 6.
5
Development and validation of a prediction model for postoperative pneumonia in patients who received spinal surgery: A retrospective study.接受脊柱手术患者术后肺炎预测模型的开发与验证:一项回顾性研究。
Heliyon. 2024 Apr 23;10(9):e29845. doi: 10.1016/j.heliyon.2024.e29845. eCollection 2024 May 15.
6
RNA modifications in pulmonary diseases.肺部疾病中的RNA修饰
MedComm (2020). 2024 May 3;5(5):e546. doi: 10.1002/mco2.546. eCollection 2024 May.
7
Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET.三联疗法对 GOLD 分组 C 和 D 患者疾病负担的影响:COSYCONET 观察性 COPD 队列研究结果。
BMC Pulm Med. 2024 Mar 1;24(1):103. doi: 10.1186/s12890-024-02902-4.
8
Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK.在英国常规临床实践中,根据 GOLD A 和 B 对 COPD 患者进行分类,与首次加重相关的风险因素。
Int J Chron Obstruct Pulmon Dis. 2023 Nov 21;18:2673-2685. doi: 10.2147/COPD.S413947. eCollection 2023.
9
Iran Quality of Care in Medicine Program (IQCAMP): Design and Outcomes.伊朗医疗保健质量提升计划(IQCAMP):设计与结果。
Arch Iran Med. 2023 Mar 1;26(3):126-137. doi: 10.34172/aim.2023.21.
10
Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives.生物制剂治疗慢性炎症性肺部疾病:最新进展与未来展望。
Front Immunol. 2023 Jun 2;14:1207641. doi: 10.3389/fimmu.2023.1207641. eCollection 2023.